CVD combo filed for rare tumor in Japan after push comes to shove
This article was originally published in Scrip
Pressure from patient groups and the Japan Endocrine Society has led, by way of official channels, to a filing by three firms in Japan for the approval of a combination therapy for pheochromocytoma, a rare form of neuroendocrine tumor.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.